Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ipilimumab: Preliminary Phase II data

Top-line, 6-month data from the open-label, international Phase II 008 trial in 150 patients showed that ipilimumab

Read the full 172 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE